Company ProfilePremium

BWX Limited

Company Profile Analysis

Ticker: BWX.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
BWX Limited - Company showcase

Year Founded & Workforce

2007

100 Employees

BWX Limited logo

BWX Limited Employee Contacts

19 verified contactsNames, job titles, seniority and locations

View Employee Contacts

BWX Limited Overview

At its peak BWX Limited was Australia's leading listed pure-play in natural beauty and personal care: a vertically integrated developer, manufacturer, distributor and marketer of branded skin, body and hair care, built around the mass-market natural brand Sukin and extended through acquisitions into the United States (Andalou Naturals, Mineral Fusion), direct-to-consumer ethical e-commerce (Nourished Life, Flora & Fauna) and a majority stake in celebrity-founded Go-To Skincare. Its thesis was compelling — a structurally growing "clean" category, owned manufacturing in Victoria, and wide grocery and pharmacy distribution through Coles, Woolworths and Chemist Warehouse. Execution failed. Serial acquisitions, an ERP disruption, China export softness, a costly new Clayton factory, retailer destocking, revenue-recognition problems and a A$322.6 million intangible write-down in FY2022 left the group over-levered to CBA. It collapsed into administration in April 2023, was broken up and sold brand by brand, and is now a liquidated shell with no operating business.


What the company did. BWX described itself in its ASX materials as a vertically integrated developer, manufacturer, distributor and marketer of branded personal care products with an emphasis on the natural segment of the market (North Castle Partners release on the Mineral Fusion sale; Motley Fool company profile). Its later investor framing, used in its August 2021 CEO Connect presentation, was "natural beauty and wellness for the world."

Business model. BWX was a branded consumer-products owner. Value creation came from (a) formulating natural-positioned products, (b) manufacturing a large share of volume in-house in Victoria (Dandenong South, then a new facility at Clayton), (c) selling wholesale to grocery, pharmacy and specialty retailers in Australia, the US, Canada and export markets, and (d) selling direct-to-consumer through owned e-commerce platforms (Nourished Life from 2017; Flora & Fauna from 2021) that also stocked third-party brands.

Revenue model mix. Essentially 100% product revenue. There was no subscription, licensing or service revenue of significance. Within product revenue, the mix was:

Value-chain position. Mid-to-upstream: product development, contract and owned manufacturing, brand marketing, and wholesale distribution, with a partial move downstream into owned retail via e-commerce marketplaces.

Customer types and end-markets. Mass grocery (Coles from September 2017; Woolworths), pharmacy (Chemist Warehouse strategic partnership; Priceline), natural specialty grocery in North America (Whole Foods Market, Sprouts Farmers Market), mass retail in Canada (Walmart Canada), cross-border Chinese e-commerce, and end consumers directly via online stores. End-market: natural and "clean" beauty and personal care (skincare, body care, hair care, cosmetics), adjacent ethical household, baby and pet products via Flora & Fauna.

Independent characterisation. BWX was a sub-scale consumer roll-up with one genuinely strong local asset (Sukin, a top-selling natural skincare brand in Australian supermarkets and pharmacy) surrounded by acquired brands bought at full prices with debt and equity. The portfolio lacked operating synergy: US brands sold through different channels than Sukin, Go-To was explicitly run independently and did not use BWX manufacturing, and the e-commerce marketplaces were low-margin retail businesses grafted onto a manufacturer. The model depended on continuous growth to service acquisition goodwill and capex; when retailer destocking, inflation and execution failures hit in FY2022, the leverage and intangible-heavy balance sheet left no buffer.

Strategy

Stated strategy (last active period, FY2021–FY2022). BWX's August 2021 materials articulated a "natural beauty and wellness for the world" vision with a multi-year strategic roadmap whose themes were: (1) leverage the structural shift toward natural, ethical and purpose-driven consumption; (2) accelerate core brands Sukin, Andalou Naturals and Mineral Fusion through strategic retail partnerships (Chemist Warehouse, Woolworths, Walmart Canada); (3) build a direct-to-consumer business unit, led by Julie Mathers, combining Flora & Fauna and Nourished Life into an ethical online retail platform; (4) add a premium skincare engine via the Go-To partnership; and (5) bring manufacturing capacity in-house at the Clayton facility from December 2021.

Initiatives in the final 24 months of operation

Medium-term targets. The last formal targets were FY2023 guidance of A$260–270m revenue and A$45–49m EBITDA (28 June 2022), cut in early 2023 to A$170–190m revenue (from an intermediate A$205–230m) with 2H FY2023 EBITDA of A$5–12m. None were met.

Products & Services

All brands below are now owned by third parties; ownership after BWX is noted.

Pricing models were standard wholesale/retail pricing; individual SKU price architecture was not publicly disclosed by BWX.

Product Portfolio

BrandCategory / descriptionTarget customerLaunchChannels under BWXPricing tierCurrent owner

Sukin

Natural skin, body and hair care; flagship mass-natural brand; carbon-neutral and vegan positioning

Mass-market Australian consumers seeking affordable natural products

2,007

Coles, Woolworths, Chemist Warehouse, pharmacy, export incl. China cross-border, US (from 2H FY18)

Mass / value-natural

PNB Consolidated (John Humble), from Jan 2024

Derma Sukin

Sensitive-skin / dermatological extension of Sukin

Sensitive-skin consumers

—

Pharmacy, grocery

Mass

Transferred with Australian business (not separately confirmed)

Andalou Naturals

Fruit stem-cell science skincare and hair care; first Non-GMO Project Verified beauty brand; 125+ SKUs

Premium natural-channel shoppers in North America, Europe, Asia

2,010

Whole Foods, Sprouts, natural specialty, mass expansion

Premium natural

The Seaweed Bath Co., from Jul 2024

Mineral Fusion

Mineral cosmetics plus hair, body, skin and nail care; hypoallergenic, free of gluten, parabens, phthalates, synthetic fragrance, talc; primarily vegan; EWG-verified

Clean-beauty cosmetics buyers

2,007

~3,000 stores incl. Whole Foods at acquisition; own e-commerce

Mid / premium

The Seaweed Bath Co., from Jul 2024

Nourished Life

Online natural and organic beauty and wellness marketplace; ~3,500 SKUs at acquisition

Australian online ethical shoppers

Founded by Irene Falcone; acquired 2017

Own website, club membership

Marketplace

Julie Mathers / HealthPost, from Apr 2023

Life Basics

Nourished Life private label (launched Feb 2017); also a natural hand sanitiser launched in 2020

Nourished Life customers

2,017

Nourished Life

Value

Transferred with Nourished Life

Flora & Fauna

Online ethical, vegan, cruelty-free marketplace; ~10,000 SKUs across 10 categories (beauty, personal care, lifestyle, baby and kids, pet, food and health); ~94,000 active customers; Sydney warehouse store opened 2019

Purpose-driven younger consumers

2,014

Own website

Marketplace

Julie Mathers / HealthPost, from Apr 2023

Go-To Skincare (50.1%)

Simple, efficacious premium skincare founded by Zoë Foster Blake; independently managed; did not use BWX manufacturing

Premium skincare consumers, Australia and international

2,014

Mecca, own DTC, international

Premium

Zoë Foster Blake and Paul Bates, from Dec 2023

USpa

Spa-style body care

Mass

—

Grocery/pharmacy

Mass

—

Edward Beale

Hair care

Mass

—

Grocery/pharmacy

Mass

—

Renew Skincare

Skincare

Mass

—

Grocery/pharmacy

Mass

—

Purely Byron (48% investment)

Beauty brand co-founded by Elsa Pataky

Premium

——

Premium

Entered administration (DW Advisory) in early 2023

Sukin natural hand sanitiser

Rapid COVID-19 product launch

Mass

2,020

Grocery, pharmacy, online

Mass

With Sukin

Financial Narrative

Scope: The last five fiscal years for which BWX reported full-year numbers are FY2018–FY2022. BWX never published FY2023 results; the only FY2023 data is 1H FY2023 and guidance.

Income statement

Sources and notes:

  • FY2018: Kalkine Media, 29 Aug 2018 (revenue, underlying EBITDA, statutory NPAT A$19.2m, basic EPS 17c, total dividend 7.45c fully franked). Underlying NPAT was A$24.2m (Kalkine, Oct 2018). FY2018 growth of 105% per Kalkine; acquisitions contributed ~A$79m.

  • FY2019 and FY2020: BWX FY2020 results release (ASX, 21 Aug 2020). FY2020 EBITDA A$27.5m pre-AASB 16; A$30.9m post-AASB 16.

  • FY2021: Finance News Network report of BWX FY2021 results (revenue A$194.1m, EBITDA A$34.5m, NPAT A$23.7m, final dividend 3.1c).

  • FY2022: Business News Australia reporting of audited FY2022 results. Conflict: the 28 June 2022 guidance had indicated ~A$206m revenue and A$6–10m EBITDA; audited revenue came in at A$198.3m and EBITDA at -A$6.4m. The A$335.6m statutory loss included a A$322.6m non-cash intangible impairment.

Margins (%)

Margins computed from table 6.1 values (FY2020 EBITDA margin on the pre-AASB 16 basis).

Revenue CAGR FY2018–FY2022: approximately 7.5% per annum (A$148.7m to A$198.3m over four years). Excluding acquired revenue, organic growth was substantially lower; Sukin organic growth in FY2018 was only 6.1% (Kalkine).

Half-year data, final reporting periods

Notes: 1H FY2018 normalised figures per Motley Fool (Mar 2018). 1H FY2020 per BWX release (underlying NPAT A$4.2m). 1H FY2021 per Kalkine. 1H FY2023 per Business News Australia (Feb 2023); revenue fell 18.4% and 1H FY2022 revenue (≈A$97.7m) is derived from that decline rate. 1H FY2022 EBITDA and loss values are as quoted in the 1H FY2023 comparison.

Balance sheet

Notes: FY2018 net cash A$19.89m and D/E 0.19x per Kalkine (Oct 2018). FY2019 net cash ~A$12m per BWX 1H FY2020 release (which reported net cash rising to A$14m at 31 Dec 2019). FY2022 value is the midpoint of the A$58–62m pro-forma net debt guided on 28 June 2022 (post-raise basis). Intangibles rose by more than 50% to about A$465m at 31 Dec 2021 from about A$300m a year earlier (ShareCafe, June 2022) — the base for the A$322.6m FY2022 impairment. At administration, net bank debt was reported at about A$120m (Power Retail) and debts owed to CBA at almost A$105m (Personal Care Insights) — a discrepancy likely reflecting gross vs. net measures and timing. At 31 Dec 2022, current assets exceeded current liabilities by A$14.2m, but only because CBA had granted an unconditional covenant waiver.

Cash flow

Notes: 1H FY2021 operating cash flow was A$9.81m (Kalkine). Buybacks: none identified.

Ratios

Directionally: ROE turned massively negative in FY2022 given a statutory loss exceeding A$335m against an equity base that had been inflated by acquisition intangibles; net debt/EBITDA became undefined (negative EBITDA) in FY2022, which is why CBA had to suspend covenant testing for the 30 June and 30 September 2022 test dates.

Commentary on trends and inflections

FY2018 — the high-water mark. Revenue doubled on acquisitions and underlying EBITDA margin reached about 27%, a premium level for personal care, driven by Sukin's high-margin domestic and export sales. But the quality was already deteriorating: Sukin's growth decelerated from 59% to 17% half-on-half (1H FY2018), and EBITDA landed below the A$42–48m guidance range.

FY2019 — first break. Revenue flatlined at A$149.5m and EBITDA fell nearly half to A$21.3m. Three drivers were disclosed in the December 2018 update: softer export sales into China (amid the US–China trade war), loss of momentum in the US brands during a management transition, and Sukin ERP start-up problems. A second downgrade followed as unprofitable promotions and excess stock were cycled.

FY2020–FY2021 — COVID-era recovery. Under Dave Fenlon revenue rose 26% to A$187.7m in FY2020 with Sukin up 55%, aided by distribution gains and a quickly launched hand sanitiser. FY2021 delivered A$194.1m revenue and A$23.7m NPAT, with new partnerships at Chemist Warehouse, Woolworths and Walmart Canada. However, revenue growth slowed to ~3%, and some FY2021 revenue was later questioned for recognition timing.

FY2022 — collapse. Management guided in May 2022 to A$233–243m revenue and A$27–30m EBITDA; by June that had fallen to ~A$206m and A$6–10m; audited results showed A$198.3m revenue, negative A$6.4m EBITDA and a A$335.6m statutory loss. Drivers: retailer destocking, inflation and a cautious consumer, the Chemist Warehouse equity-linked expense, acquisition costs, integration failures and Clayton capex. Remarkably, management simultaneously guided FY2023 revenue of A$260–270m and EBITDA of A$45–49m, which commentators at the time viewed as implausible.

1H FY2023 — terminal. Revenue fell 18.4% to A$79.7m and EBITDA was negative A$29.7m. Out-of-stocks (from working-capital constraint) compounded destocking, and the full-year revenue guide was cut first to A$170–190m and then implicitly abandoned. Administration followed within six weeks of the result.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Reporting Structure by Period

PeriodReporting structure (as disclosed / referenced)

FY2016–FY2017

Effectively single-brand (Sukin) with domestic and export reporting

FY2018–FY2020

Brand-based disclosure: Sukin, Andalou Naturals, Nourished Life, Mineral Fusion, other brands

FY2021–FY2022

Brand-based disclosure plus Go-To and Flora & Fauna; operating segments by channel/geography

1H FY2023 (final)

Commentary references Australia, International, Digital and USA business segments, plus Go-To

Revenue by Segment

Brand (AUD Mn)FY2019FY2020

Sukin net sales

52.781.7

Andalou Naturals net sales

48.553.3

Nourished Life net sales

21.024.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Revenue by Segment (Half-Yearly)

Brand (AUD Mn)1H FY20191H FY2020

Sukin

23.233.1

Andalou Naturals

22.726.2

Nourished Life

10.811.3

Group Entities

EntityACNRole

BWX Limited

163 488 631

Listed parent

Beautiworx Pty Ltd

163 847 916

Main operating company

LHS No. 2 Pty Ltd

165 455 201

Holding entity

Sapu Corporation Pty Ltd (formerly Uspa Corporation)

163 273 514

USpa brand entity

Edward Beale Hair Care Pty Ltd

167 891 161

Edward Beale brand

BWX Brands Pty Ltd

602 062 117

Brand holding

BWX Australia Pty Ltd

601 966 170

Australian operations

Sukin Australia Pty Ltd

602 062 199

Sukin brand

Renew Skin Care Australia Pty Ltd

606 139 315

Renew brand

Derma Sukin Australia Pty Ltd

606 140 818

Derma Sukin brand

Lightning Distribution Pty Ltd

610 861 455

Distribution

BWX Digital Pty Ltd

621 403 370

Nourished Life / digital

The Good Collective Pty Ltd

169 556 398

Flora & Fauna

Income Statement and Margin Analysis (%)

MetricFY2018FY2019FY2020FY2021FY2022

Net revenue (AUD Mn)

148.7149.5187.7194.1198.3

Revenue growth YoY (%)

105.00.525.63.42.2

EBITDA, underlying/normalised (AUD Mn)

40.321.327.534.5-6.4

Statutory NPAT (AUD Mn)

19.29.515.223.7-335.6

Basic EPS (AUD cents)

17.0————

Dividends per share (AUD cents)

7.45————

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2018FY2019FY2020FY2021FY2022

EBITDA margin (%)

27.114.214.717.8-3.2

Net margin (%)

12.96.48.112.2-169.2

Income Statement

Metric1H FY20181H FY20201H FY20211H FY20221H FY2023

Revenue (AUD Mn)

67.284.184.597.779.7

EBITDA (AUD Mn)

17.5——5.4-29.7

Statutory NPAT (AUD Mn)

——9.85-5.4-100.8

Key Financials and Financial Ratios (x)

MetricFY2018FY2019FY2022

Net cash (+) / net debt (-) (AUD Mn)

19.912.0-60.0

Debt to equity (x)

0.19——

Balance Sheet

MetricFY2021FY2022

Equity raised (AUD Mn)

100.023.2

Valuation Snapshot

MetricValue

Listing date

11 November 2015

Price on 8 Aug 2018

A$4.99 (market cap ~A$665m)

Price on FY2021 result (pre-halt, Aug 2021)

A$5.31

2022 high

A$5.56

June 2022 capital raise price

A$0.60

Price at June 2022 (post-announcement)

A$0.695 (Market Matters)

Last vendor-quoted price (1 May 2024)

A$0.20 (InvestSMART; delisted)

1-, 3-, 5-year return to Oct 2026

Not meaningful — delisted; equity value effectively nil

Per-Share Data

MetricFY2018FY2021FY2022

Total DPS (AUD cents)

7.45—0

Final DPS (AUD cents)

4.23.10

Analyst Conclusions

Management guidance / consensus: None. The company is in liquidation, has no operating business, no management, and no analyst coverage. The only remaining value-relevant events are the liquidators' final distributions and eventual deregistration.

Bull-case arguments (for the brands, not the shell)

  1. Sukin retained franchise value: the brand plus factory realised roughly A$70m in a contested process, and its founder repurchased it, suggesting confidence in its standalone economics.

  2. Andalou and Mineral Fusion were acquired as a platform by The Seaweed Bath Co. with Natureza Growth Partners backing, implying the US brands remain viable.

  3. Go-To and Flora & Fauna returned to founder ownership, which historically suits founder-led brands.

Bear-case arguments (for BWX Limited equity and unsecured creditors)

  1. Secured debt of roughly A$105–120m to CBA ranks ahead of everyone, and disclosed realisations (A$21.8m Go-To plus ~A$70m Sukin) plus undisclosed digital and US proceeds give little visible surplus after receivers' and administrators' costs.

  2. Ordinary shareholders rank last in liquidation; recovery is very likely nil.

  3. The company has been delisted and its operating subsidiaries sold, so there is no residual business to recapitalise.

Catalysts and monitorables (next 12 months)

  • Any further liquidators' reports or dividend notices to creditors (FTI creditors portal).

  • Any public examination, insolvent-trading or voidable-transaction claims arising from the 9 August 2024 statutory report.

  • Any ASIC action relating to FY2021–FY2022 financial reporting.

  • Deregistration of BWX Limited and its subsidiaries.

  • Performance of the successor owners: Sukin under PNB Consolidated; Andalou and Mineral Fusion under Seaweed Bath Co.

Concluding analyst verdict

BWX Limited is a closed case rather than an investment proposition. The listed entity has no assets of operating substance, no listing, no management and no prospect of equity recovery, and it should be treated in any coverage universe as a written-off, liquidated holding. The analytical value of the dossier lies in the lessons. BWX demonstrates how a genuinely good domestic brand can be overwhelmed by the capital structure built around it. Sukin was profitable, well distributed and loved enough by consumers that its founder paid around A$70 million to buy it back out of receivership. Yet between 2017 and 2021 the group layered on Andalou Naturals, Mineral Fusion, Nourished Life, Flora & Fauna and a 50.1% stake in Go-To at full prices, funded by bank debt and dilutive equity, while committing to a new factory. Each acquisition widened the gap between headline revenue growth and organic performance, and intangibles swelled to around A$465 million on a business that never earned more than about A$40 million of EBITDA. When FY2022 brought retailer destocking, inflation, an expensive pharmacy partnership and accounting problems with revenue recognition, earnings vanished, the A$322.6 million impairment followed, and the lender's patience ran out within ten months. Governance signals were visible well before the end: repeated guidance misses from 2018 onward, a failed management buyout, rapid CEO turnover, and wildly optimistic FY2023 targets issued alongside an emergency raise. The receivers then realised a fraction of what had been paid: Go-To returned for A$21.8 million against roughly A$89 million invested. For investors in consumer roll-ups, BWX is a textbook warning about paying for growth with leverage, the fragility of retailer-dependent revenue, and the importance of separating organic from acquired growth. Final verdict: no investment case; equity value nil; monitor only for liquidation outcomes and any regulatory follow-up.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleTenureNotes

Thinus Keeve

Group CEO & Managing Director

Appointed 27 Feb 2023

Appointed after the 1H FY2023 result; in office at administration

Mark (Marcus) Anthony Derwin

Non-Executive Director

Appointed 10 Feb 2023

Board refresh during crisis

Lisa Ronson

Non-Executive Director

Appointed 26 Feb 2023

Previously director of The Reject Shop (since 2019) and Laybuy (since 2021) per Motley Fool profile

Birol Akdogan

Chief Financial Officer

At least 2023

Declined comment on Purely Byron administration

Rory Gration

CEO

1 Mar 2022 – Feb 2023

Departed with immediate effect alongside the A$100.8m half-year loss

Dave Fenlon

Group CEO & MD

c. 2019 – early 2022

Led FY2020–FY2021 recovery and acquisitions of Flora & Fauna and Go-To

John Humble

Founder / former CEO

To c. 2018

Led failed Bain-backed buyout; returned in 2024 as buyer of Sukin via PNB Consolidated

Julie Mathers

Founding CEO Flora & Fauna; led BWX's D2C unit from 2021

2021 – 2023

Bought Flora & Fauna and Nourished Life back in 2023

Major Shareholders

HolderSharesStake (%)

J P Morgan Nominees Australia Pty Limited

12,315,8346.16

HSBC Custody Nominees (Australia) Limited

9,078,4104.54

HSBC Custody Nominees (Australia) Limited A/C 2

7,958,2693.98

National Nominees Limited

6,167,5173.08

Neweconomy Com Au Nominees Pty Limited (900 Account)

2,079,8691.04

Netwealth Investments Limited (Wrap Service A/C)

546,2540.27

Pacific Custodians Pty Limited (BWX Employee Sub-register)

516,4980.26

Competitive Landscape

Key Competitors

CompetitorOwnerSegment overlapRelative positioning vs BWX

Burt's Bees

Clorox

US and global mass-natural

Far larger scale, US mass dominance

Alba Botanica, Avalon Organics

Hain Celestial

US natural channel skincare

Direct Andalou rival (same founders' heritage)

Weleda

Weleda AG

Global natural skincare

Premium heritage brand

Jurlique

Shanghai Jahwa

Australian premium natural

Premium-priced Australian rival

Aesop

L'Oréal (since 2023)

Premium Australian skincare

Prestige; competes with Go-To more than Sukin

Trilogy

—

ANZ natural skincare

Pharmacy-channel rival

QV / Ego Pharmaceuticals

Private

Australian pharmacy sensitive skin

Rival to Derma Sukin

Nivea

Beiersdorf

Mass skincare

Mass incumbent

Dr. Bronner's

Private

US natural body care

Natural-channel rival

Adore Beauty, Mecca

Listed / private

Online beauty retail

Rivals to Nourished Life / Flora & Fauna

Supermarket private label

Coles, Woolworths

Mass natural

Price pressure on Sukin

Peer Comparison FY2022

MetricBWX FY2021BWX FY2022

Revenue (AUD Mn)

194.1198.3

Revenue growth (%)

3.42.2

EBITDA margin (%)

17.8-3.2

Recent Developments

Note: the 18 months to October 2026 contain no company-originated news because the company is in liquidation.

Company Snapshot

$137.5M

Revenue

100

Employees

2007

Founded

Dandenong South, Australia

Headquarters

SWOT Analysis

Strengths

  • Sukin was the group's largest brand, growing net sales 55% to A$81.7m in FY2020 (BWX FY2020 release).
  • High peak profitability: FY2018 underlying EBITDA of A$40.3m on A$148.7m revenue (~27% margin).
  • Broad channel access: Coles from 2017, Chemist Warehouse and Woolworths partnerships in FY2021.
  • Owned manufacturing in Victoria, culminating in the Clayton facility.
  • Speed to market: rapidly launched natural hand sanitiser in 2020.
  • Brand assets retained value even in insolvency: Sukin realised ~A$70m and attracted strong local and international interest (Greenhill).

Weaknesses

  • Organic growth was weak beneath acquisitions: Sukin organic growth only 6.1% in FY2018.
  • Repeated guidance failures: misses in FY2018, two FY2019 downgrades, three FY2022 downgrades.
  • Accounting control failures: revenue-recognition issues for FY2021 and 1H FY2022 delayed FY2022 accounts.
  • Intangible-heavy balance sheet: intangibles ~A$465m at Dec 2021, followed by a A$322.6m impairment.
  • Integration failures and limited synergies; Go-To used no BWX manufacturing.
  • Working-capital starvation causing out-of-stocks in 1H FY2023.

Opportunities

  • Structural growth of natural/vegan beauty (US$20.8bn vegan cosmetics forecast by 2025).
  • US mass-market expansion for Andalou, Sukin and Mineral Fusion (identified by Moelis as the largest opportunity).
  • Cross-selling across Flora & Fauna and Nourished Life platforms.
  • China cross-border e-commerce (Tmall, JD.com performed in line in FY2019).
  • Pharmacy channel leverage via Chemist Warehouse.
  • Sustainable packaging innovation trials.

Threats

  • Retailer destocking, cited as a primary cause of the April 2023 administration.
  • Lender enforcement: CBA covenant relief ended and receivers were appointed on 4 April 2023.
  • Macro pressure: inflation, rates and cautious consumer cited for FY2022.
  • Cyber risk: malicious code on the Flora & Fauna website.
  • Contingent obligations: Go-To put option over the remaining 49.9%, with a reported floor around A$93m in 2022.
  • Investee failures: Purely Byron (48% owned) entered administration.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2022Guidance cut to A$233–243m revenue, A$27–30m EBITDA; shares fall 22%Credibility loss
28 Jun 2022Revenue guide cut to ~A$206m, EBITDA A$6–10m; A$23.2m raise at A$0.60; CBA covenant suspensionLiquidity crisis
26 Aug 2022Cannot lodge FY2022 accounts; revenue-recognition issues for FY2021 and 1H FY2022Accounting failure
28 Sept 2022Further delay to audited accountsEscalation
30 Sept 2022Securities suspended until audited FY2022 resultsTrading halt
28 Oct 2022Accounts now expected mid-November; AGM deferred beyond 30 Nov 2022Governance strain
Late 2022FY2022 statutory loss A$335.6m incl. A$322.6m impairment; auditors flag expected 1H FY23 lossBalance-sheet reset
Late 2022 / early 2023Malicious code inserted into Flora & Fauna website disclosedCyber incident
Early 2023Q2 sales well below target; FY2023 revenue guide cut to A$170–190mDowngrade
10 Feb 2023Marcus Derwin joins boardBoard refresh
Feb 20231H FY2023: revenue A$79.7m, loss A$100.8m; CEO Rory Gration departsFinal result
26–27 Feb 2023Lisa Ronson joins board; Thinus Keeve appointed CEO & MDCrisis leadership
Early 2023Purely Byron (48% investee) enters administrationInvestment loss
23 Mar 2023Trading haltPre-insolvency
3 Apr 2023Voluntary administrators (FTI) appointed to 13 Australian entitiesInsolvency
4 Apr 2023CBA appoints KPMG receivers and managersSecured enforcement
Apr 2023Flora & Fauna and Nourished Life sold to Julie Mathers and HealthPostFirst disposal
19 Apr 2023Administrators issue Shareholders FAQShareholder communication
May 2023Grant Samuel to sell Go-To stake; KPMG US to sell US brandsSale processes
1 and 8 May 2023Administrators' circulars; court extension ordersProcess
Jun 2023Greenhill appointed to sell Sukin and Clayton facilityCore asset sale launched
Oct 2023Administrators' circulars (20, 23, 27 Oct); second court extensionProcess
Dec 2023Go-To stake sold to Foster Blake and Bates for A$21.8mDisposal
12 Jan 2024Sukin sold to PNB Consolidated (John Humble), ~A$70m reportedDisposal
30 Apr 2024Removed from ASX Official ListDelisting
10 May 2024Group enters liquidationTerminal
Jul 2024Andalou Naturals and Mineral Fusion sold to The Seaweed Bath Co.Final brand disposal
9 Aug 2024Liquidators' Statutory Report to CreditorsLast identified public document

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment (FY2019–FY2020): Sukin net sales rose from AUD 52.7 Mn in FY2019 to AUD 81.7 Mn in FY2020.
BWX Limited — Revenue by Segment (FY2019–FY2020)
Series (AUD Mn)FY2019FY2020
Sukin net sales52.781.7
Andalou Naturals net sales48.553.3
Nourished Life net sales2124.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. ASX Compliance, "BWX Limited (ASX: BWX) – Removal from Official List", 30 April 2024 (via quoteapi.com).
  2. BWX Limited ASX releases: Trading update 20 Dec 2018; 1H FY2020 results 21 Feb 2020; FY2020 results 21 Aug 2020; Capital raise and guidance 28 Jun 2022; CEO Connect presentation Aug 2021 (asx.com.au; Bell Potter mirror).
  3. FTI Consulting, BWX Group (In Liquidation) creditors portal (fticonsulting.com)
  4. KPMG Australia, BWX Group receivership page and Circular to Creditors & Suppliers, 4 April 2023.
  5. KPMG Corporate Finance LLC, "Exclusive financial advisor to BWX Limited" (sale of Andalou Naturals and Mineral Fusion).
  6. Business News Australia: Sukin sale to PNB Consolidated; Go-To stake sale process; Greenhill appointment; FY2023 downgrade and FY2022 results; Rory Gration exit and 1H FY2023 loss; administration announcement.
  7. Personal Care Insights, 12 Jan 2024 (Sukin acquisition by PNB Consolidated).
  8. Power Retail and Inside Retail (April 2023) on administration and receivership.
  9. SmartCompany (Go-To stake, put option, Flora & Fauna acquisition).
  10. Internet Retailing (Nourished Life and Flora & Fauna acquisitions).
  11. BeautyMatter and CB Insights (Seaweed Bath Co. acquisitions, July 2024).
  12. North Castle Partners (Mineral Fusion sale to BWX).
  13. FNArena (Andalou acquisition terms; Flora & Fauna analysis, May 2021).
  14. Kalkine / Kalkine Media (FY2018 results; FY2022 accounts delay; 1H FY2021).
  15. Finance News Network (FY2021 results).
  16. ShareCafe and Market Matters (June 2022 downgrade and raise).
  17. Motley Fool Australia (BWX ticker profile, top holders, delisting date; March 2018 analysis).
  18. InvestSMART (last quoted price; director appointment dates).
  19. Statista (BWX brand revenue chart notes, FY2021–FY2022).
  20. Stocks Down Under (share price history commentary).

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.